In this context, our study employs BxPC3 cells (KRAS-wildtype (WT); TP53 mutant) and PANC1 cells (KRAS-mutant G12D; TP53 mutant) to elucidate the mechanisms underlying pancreatic cancer chemoresistance and identify potential therapeutic targets. This evidence concerns the gene KRAS and pancreatic neoplasm.